• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MET-Mutated NSCLC with Major Response to Crizotinib.

作者信息

Mendenhall Melody A, Goldman Jonathan W

机构信息

The David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, California.

The David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, California.

出版信息

J Thorac Oncol. 2015 May;10(5):e33-e34. doi: 10.1097/JTO.0000000000000491.

DOI:10.1097/JTO.0000000000000491
PMID:25898965
Abstract
摘要

相似文献

1
MET-Mutated NSCLC with Major Response to Crizotinib.对克唑替尼有显著反应的MET突变型非小细胞肺癌
J Thorac Oncol. 2015 May;10(5):e33-e34. doi: 10.1097/JTO.0000000000000491.
2
MET Mutation Associated with Responsiveness to Crizotinib.与克唑替尼反应性相关的MET突变
J Thorac Oncol. 2015 May;10(5):e29-e31. doi: 10.1097/JTO.0000000000000478.
3
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.在具有MET外显子14跳跃突变的非小细胞肺癌中，卡博替尼克服克唑替尼对获得性耐药突变MET D1228N的耐药性。
JCO Precis Oncol. 2021 Nov;5:849-853. doi: 10.1200/PO.21.00076.
4
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.MET 外显子 14 跳跃型非小细胞肺癌中克唑替尼耐药的预先存在 MET Y1230C 突变的出现
J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.
5
Crizotinib in the management of advanced-stage non-small-cell lung cancer.克唑替尼用于晚期非小细胞肺癌的治疗
Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.
6
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.一例携带MET剪接位点突变的肺腺癌患者对克唑替尼的反应
Clin Lung Cancer. 2015 Sep;16(5):e101-4. doi: 10.1016/j.cllc.2015.01.009. Epub 2015 Feb 7.
7
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中MET外显子14跳跃导致克唑替尼耐药的获得性机制
J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.
8
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.一名从未吸烟的肺腺癌患者，存在MET外显子14突变（D1028N），接受克唑替尼治疗后出现快速部分缓解。
Invest New Drugs. 2016 Jun;34(3):397-8. doi: 10.1007/s10637-016-0332-0. Epub 2016 Feb 18.
9
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.获得性表皮生长因子受体（EGFR）突变作为MET突变肿瘤中克唑替尼潜在的耐药驱动因素。
J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18.
10
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中 MET 外显子 14 跳跃导致对克唑替尼获得性耐药。
J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.

引用本文的文献

1
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.受体酪氨酸激酶MET作为非小细胞肺癌治疗靶点的作用不断扩展。
Cell Rep Med. 2025 Mar 18;6(3):101983. doi: 10.1016/j.xcrm.2025.101983. Epub 2025 Feb 27.
2
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment.揭示 HGF/c-Met 信号在非小细胞肺癌肿瘤微环境中的作用。
Int J Mol Sci. 2024 Aug 22;25(16):9101. doi: 10.3390/ijms25169101.
3
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.
MET原癌基因：对驱动恶性肿瘤的分子机制三十年的洞察
Pharmaceuticals (Basel). 2024 Mar 30;17(4):448. doi: 10.3390/ph17040448.
4
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?针对非小细胞肺癌（NSCLC）中的 MET：新的老故事？
Int J Mol Sci. 2023 Jun 14;24(12):10119. doi: 10.3390/ijms241210119.
5
Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.非小细胞肺癌患者中新的MET外显子14跳跃变异的鉴定：一种涉及计算机预测和逆转录聚合酶链反应的原型工作流程
Cancers (Basel). 2022 Oct 1;14(19):4814. doi: 10.3390/cancers14194814.
6
Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.病例报告：一名91岁的非小细胞肺癌患者，携带MET Y1003S点突变。
Front Med (Lausanne). 2022 Jan 31;8:772998. doi: 10.3389/fmed.2021.772998. eCollection 2021.
7
A narrative review of MET inhibitors in non-small cell lung cancer with exon 14 skipping mutations.外显子14跳跃突变的非小细胞肺癌中MET抑制剂的叙述性综述。
Transl Lung Cancer Res. 2021 Mar;10(3):1536-1556. doi: 10.21037/tlcr-20-1113.
8
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.针对具有MET外显子14改变的转移性非小细胞肺癌的新型疗法：卡马替尼聚焦
Lung Cancer (Auckl). 2021 Mar 18;12:11-20. doi: 10.2147/LCTT.S263610. eCollection 2021.
9
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.针对非小细胞肺癌中 MET 异常的靶向治疗方法。
Drugs. 2021 Apr;81(5):547-554. doi: 10.1007/s40265-021-01477-2. Epub 2021 Feb 27.
10
The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.卡马替尼治疗 MET 外显子 14 跳跃突变或基因扩增的晚期非小细胞肺癌的临床影响。
Cancer Res Treat. 2021 Oct;53(4):1024-1032. doi: 10.4143/crt.2020.1331. Epub 2021 Jan 29.